For full details of each session, please view the event guide.
8:30 am
Morning Coffee
9:00 am Chair’s Opening Remarks
3D/Ex Vivo Models
9:05 am Improving the Safety Predictability of IO Modalities with Organ on Chip (OoC) Models
Synopsis
- Incorporating new OoC models in IO workflow: Key aspects to consider
- How to use OoC for Efficacy Models in IO
- Challenges in safety prediction in IO and how OoC can help
- High level overview of the regulatory status regarding using OoC based IO data in submission
9:35 am Round Table Discussions:
Synopsis
Discover multiple perspectives on the key issues in preclinical development. Join a roundtable discussion that has been specifically designed to enable you to leave with insights that you can immediately implement into your preclinical model strategies
Challenges in the scale-up and wider adoption of organoid models
How familiar should preclinical scientists be with Regulatory concepts? What should be considered in preclinical study design
Will isoform-specific detection and targeting in different tumour subtypes result into a further developed personalized Medicine?
10:05 am Enabling patient-centric cancer R&D with primary tissues and Pharmacoscopy®
Synopsis
- Primary tissue are as close as one can get to an actual patient in preclinical R&D
- Quantifying drug action in these complex samples, however, is analytically very challenging
- With Pharmacoscopy® we can interrogate drug activity in live human tumour tissues at the single cell level at scale and with demonstrated clinical translatability
10:20 am
Speed Networking
10:50 am
Morning Coffee
In Vitro Assays
11:20 am Panel Discussion: To What Extent Will Ex-Vivo Platform Replace In-Vivo Models From Technical, Ethical, and Regulatory Standpoints?
12:00 pm RNA-Sequencing Analysis of Immunotherapy Response in Organotypic Tumor Spheroids
Synopsis
- Bulk RNA-sequencing (RNA-seq) uncovers dynamic responses to interferon-gamma versus PD- 1blockade in murine organotypic spheroids
- Development of methods to extract cells and perform single cell RNAseq refines this analysis
- These high resolution ex vivo functional studies help to uncover novel immunobiology
12:30 pm Improving Therapy and Stratification by Listening to Mitochondria
Synopsis
- If you want your drug to work in cancer, it has to kill the cancer cell
- Mitochondria decide whether or not the cancer cell dies via apoptosis
- BH3 profiling predicts whether apoptosis will occur
1:00 pm Poster Session: Showcase your work live amongst industry pioneers through a series of short poster presentations
1:40 pm
Networking Lunch
Supporting Techniques in Evaluating Therapeutic Response
2:40 pm Imaging of PD-L1 in Head and Neck Cancer in Response to Oncolytic Virotherapy
3:10 pm PK/PD from Drug Discovery to Registration: An Industry Case Study
Synopsis
- PK/PD is a key tool in drug discovery and development
- Pre-clinical PK/PD knowledge is continually informative through compound identification, dose projection, clinical study designs and drug registration
- Establishing efficacious concentrations early helps to design molecules with high potential